title: Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.
abstract: Delta9-Tetrahydrocannabinol, the main active component of marijuana, induces apoptosis of transformed neural cells in culture. Here, we show that intratumoral administration of Delta9-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2. Cannabinoid treatment did not produce any substantial neurotoxic effect in the conditions used. Experiments with two subclones of C6 glioma cells in culture showed that cannabinoids signal apoptosis by a pathway involving cannabinoid receptors, sustained ceramide accumulation and Raf1/extracellular signal-regulated kinase activation. These results may provide the basis for a new therapeutic approach for the treatment of malignant gliomas.
authors.affiliation: Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, 28040-Madrid, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Galve-Roperh
authors.forename: C
authors.initials: C
authors.lastname: Sánchez
authors.forename: M L
authors.initials: ML
authors.lastname: Cortés
authors.forename: T
authors.initials: T
authors.lastname: Gómez  del Pulgar
authors.forename: M
authors.initials: M
authors.lastname: Izquierdo
authors.forename: M
authors.initials: M
authors.lastname: Guzmán
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D017209:Apoptosis; D048588:Benzoxazines; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D002186:Cannabinoids / Q000627:therapeutic use* / Q000633:toxicity; D002518:Ceramides / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D013759:Dronabinol / Q000627:therapeutic use* / Q000633:toxicity; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D048031:JNK Mitogen-Activated Protein Kinases; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D009025:Morpholines / Q000627:therapeutic use* / Q000633:toxicity; D009281:Naphthalenes / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D013109:Sphingomyelins / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D048051:p38 Mitogen-Activated Protein Kinases
chemical_list: D000970:Antineoplastic Agents; D048588:Benzoxazines; D002186:Cannabinoids; D002518:Ceramides; D004268:DNA-Binding Proteins; D009025:Morpholines; C064769:N-acetylsphingosine; D009281:Naphthalenes; C499308:Rag2 protein, mouse; D013109:Sphingomyelins; C064655:V(D)J recombination activating protein 2; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D013759:Dronabinol; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D013110:Sphingosine